Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 8/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16068166 | 0.83 | KEAP1 (0.56) | KEAP1NFE2L2KMT2APRMT5MEN1 | |
| SCHEMBL19086277 | 0.82 | HSP90AB1 (0.52) | HSP90AB1KMT2AMEN1NAMPT | |
| SCHEMBL6038205 | 0.81 | NAMPT (0.60) | HSP90AB1KMT2AMEN1NAMPT | |
| SCHEMBL27088356 | 0.77 | KEAP1 (0.62) | KEAP1NFE2L2SMN1; SMN2KMT2APRMT5 | |
| SCHEMBL28605137 | 0.76 | MEN1 (0.65) | KEAP1NFE2L2SMN1; SMN2KMT2APRMT5 | |
| SCHEMBL6620808 | 0.72 | SIGMAR1 (0.60) | KMT2AMEN1ALDH1A1NPSR1GAA | |
| SCHEMBL5151263 | 0.71 | RAB9A (0.58) | SMN1; SMN2KMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL29758636 | 0.71 | TSHR (0.65) | SMN1; SMN2KMT2AMEN1ALDH1A1CYP3A4 | |
| SCHEMBL4960591 | 0.71 | CYP2C19 (0.59) | SMN1; SMN2KMT2AMEN1ALDH1A1NPSR1 | |
| SCHEMBL7030199 | 0.70 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1NPSR1GAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751908-B2 | Convergent processes for preparing macrolide antibacterial agents | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751908-B2 | Convergent processes for preparing macrolide antibacterial agents | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160046660-A1 | CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS | TETARD, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160046660-A1 | CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS | TETARD, INC. | 2016-02-18 | — | — | US | disclosed |
| WO-2014145210-A1 | CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS | CEMPRA PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046660-A1 | CONVERGENT PROCESSES FOR PREPARING MACROLIDE ANTIBACTERIAL AGENTS | COASY, TKT, CYP51A1 | KEAP1 2618/4885NFE2L2 4196/4885SMN1; SMN2 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.